Publications and Presentations
Balstilimab: Anti-PD-1 Antibody
European Society for Medical Oncology (ESMO) Virtual
Sept 16-21, 2021
Balstilimab (anti-PD-1) in Combination with Zalifrelimab (anti-CTLA-4): Final Results from a Phase 2 Study in Patients (pts) with Recurrent/metastatic (R/M) Cervical Cancer (CC). O'Malley, et al.
European Society for Medical Oncology (ESMO) Virtual
Sept 16-21, 2021
Balstilimab Alone or in Combination with Zalifrelimab as Second-line Treatment for Patients with Previously Treated Recurrent/metastatic Cervical Cancer: a Randomized, Placebo-Controlled Phase II Trial (RaPiDS/GOG-3028). Randall, et al.
Gynecologic Oncology
August 25, 2021
Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer. O'Malley, et al.
American Society of Clinical Oncology (ASCO)
June 3-7, 2021
Differentiated Activity Profile for the PD-1 Inhibitor Balstilimab. C.Joyce, et al.
SGO 2021 Virtual Annual Meetings on Women's Cancer Abstracts
March 19-22, 2021
RaPiDS (GOG-3028): A Randomized Phase II Study of Balstilimab (AGEN2034) as Monotherapy or in Combination with Zalifrelimab (AGEN1884) in Second-Line Cervical Cancer. O'Malley, et al.
Oncogene
January 26, 2021
Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor. Grossman, et al.
European Society for Medical Oncology (ESMO) Virtual
September 19-21, 2020
Balstilimab (anti-PD-1) Alone and in Combination with Zalifrelimab (anti-CTLA-4) for Recurrent/Metastatic (R/M) Cervical Cancer (CC) Preliminary Results of Two Independent Ph2 Trials . O'Malley, et al.
Society for Immunotherapy of Cancer (SITC)
November 6-10, 2019
Single-agent Activity of a Novel PD-1 Inhibitor, AGEN2034, in Recurrent Ovarian Cancer. O’Malley, et al.
European Society for Medical Oncology (ESMO)
October 19-23, 2018
Phase 1/2, Open-Label, Multiple Ascending Dose Trial of AGEN2034, an Anti–PD-1 Monoclonal Antibody, in Advanced Solid Malignancies: Results of Dose Escalation in Advanced Cancer and Expansion Cohorts in Subjects With Relapsed/Refractory Cervical Cancer. Drescher, et al.
European Society for Medical Oncology (ESMO)
October 19-23, 2018
Phase 1/2 Study of CTLA-4 Inhibitor AGEN1884 + PD-1 Inhibitor AGEN2034 in Patients With Advanced/Refractory Solid Tumors, With Expansion Into Second-Line Cervical Cancer and Solid Tumors. Coward et al.
American Society of Clinical Oncology (ASCO)
June 1-5, 2018
Phase One Open-Label, Ascending Dose Trial of AGEN2034, an Anti-PD-1 Monoclonal Antibody, in Advanced Solid Malignancies: Results of Dose Escalation. Moore, et al.
American Association for Cancer Research (AACR)
April 14-18, 2018
Evaluation of Peripheral T Cell Subset Proliferation as a Pharmacodynamic Assay to Guide the Development of Anti-CTLA-4 and PD-1 Antibody Combinations in Patients With Solid Tumors. de Souza, et al.
Society for Immunotherapy of Cancer (SITC)
November 9-12, 2017
AGEN2034, a Novel anti-PD-1 Antibody that Combines Effectively With CTLA-4 Pathway Blockade to Enhance T Cell Activity. Chand, et al.
Zalifrelimab: Anti-CTLA-4 Antibody
European Society for Medical Oncology (ESMO) Virtual
Sept 16-21, 2021
Balstilimab (anti-PD-1) in Combination with Zalifrelimab (anti-CTLA-4): Final Results from a Phase 2 Study in Patients (pts) with Recurrent/metastatic (R/M) Cervical Cancer (CC). O'Malley, et al.
European Society for Medical Oncology (ESMO) Virtual
Sept 16-21, 2021
Balstilimab Alone or in Combination with Zalifrelimab as Second-line Treatment for Patients with Previously Treated Recurrent/metastatic Cervical Cancer: a Randomized, Placebo-Controlled Phase II Trial (RaPiDS/GOG-3028). Randall, et al.
Society for Immunotherapy of Cancer (SITC)
November 9-14, 2020
Pseudoprogression (PSP) Patterns: Analysis from 2 Independent Phase-2 Studies with Immunotherapy for Recurrent Cervical Cancer. O'Malley, et al.
Society for Immunotherapy of Cancer (SITC)
November 9-14, 2020
Single-agent Zalifrelimab (anti-CTLA-4) Shows Clinical Benefit in Rare Tumors – Case Reports from a Phase 2 Study (NCT02694822). Perez, et al.
European Society for Medical Oncology (ESMO) Virtual
September 19-21, 2020
Balstilimab (anti-PD-1) Alone and in Combination with Zalifrelimab (anti-CTLA-4) for Recurrent/Metastatic (R/M) Cervical Cancer (CC) Preliminary Results of Two Independent Ph2 Trials . O'Malley, et al.
Journal for ImmunoTherapy of Cancer
August 8, 2019
Angiosarcoma Patients Treated with Immune Checkpoint Inhibitors: A Case Series of Seven Patients from a Single Institution. Florou, et al.
PLOS
April 4, 2018
Toxicological and Pharmacological Assessment of AGEN1884, a Novel Human IgG1 anti-CTLA-4 Antibody. Gombos, et al.
European Society for Medical Oncology (ESMO)
October 19-23, 2018
Phase 1/2 Study of CTLA-4 Inhibitor AGEN1884 + PD-1 Inhibitor AGEN2034 in Patients With Advanced/Refractory Solid Tumors, With Expansion Into Second-Line Cervical Cancer and Solid Tumors. Coward, et al.
American Society of Clinical Oncology (ASCO)
June 1-5, 2018
Phase One Open-Label, Ascending Dose Trial of AGEN1884, an Anti-CTLA-4 Monoclonal Antibody, in Advanced Solid Malignancies: Dose Selection for Combination with PD-1 Blockade. Wilky, et al.
American Association for Cancer Research (AACR)
April 14-18, 2018
Evaluation of Peripheral T Cell Subset Proliferation as a Pharmacodynamic Assay to Guide the Development of Anti-CTLA-4 and PD-1 Antibody Combinations in Patients With Solid Tumors. de Souza, et al.
Society for Immunotherapy of Cancer (SITC)
November 9-12, 2017
Characterization of the anti-CTLA-4 Antibody AGEN1884, Including Toxicology and Pharmacology Assessments in Non-human Primates. Gombos, et al.
American Society of Clinical Oncology (ASCO)
June 2-6, 2017
Phase 1, Open-Label, Multiple-Ascending-Dose Trial of AGEN1884, an Anti–CTLA-4 Monoclonal Antibody, in Advanced Solid Malignancies. Wilky, et al.
American Association for Cancer Research (AACR)
April 1-5, 2017
AGEN1884, an IgG1 anti-CTLA-4 Antibody, Combines Effectively with PD-1 Blockade in Primary Human T Cell Assays and in a Non-human Primate Pharmacodynamic (PD) Model. Drouin, et al.
American Association for Cancer Research (AACR)
April 16-20, 2016
AGEN1884 and AGEN2041: Two Functionally Distinct anti-CTLA-4 Antagonist Antibodies. Drouin, et al.
AGEN1181: Multipurpose, second-generation CTLA-4
American Association for Cancer Research (AACR)
April 9-14, 2021
Fc-enhanced anti-CTLA-4 Antibody, AGEN1181: New Mechanistic Insights for Potent Antitumor Immunity and Combination Potential in Treatment-resistant Solid Tumors. Tanne, et al.
American Association for Cancer Research (AACR)
April 9-14, 2021
Characterization of The Pharmacodynamic Activity of AGEN1181, an Fc-enhanced CTLA-4 Antibody, Alone and in Combination With the PD-1 Antibody Balstilimab. Shapiro, et al.
Society for Immunotherapy of Cancer (SITC)
November 9-14, 2020
AGEN1181, an Fc engineered anti-CTLA-4 antibody, demonstrates clinical activity, alone or in combination with balstilimab (anti-PD-1), and broadens the therapeutic potential of CTLA-4 therapy. O'Day, et al.
American Association for Cancer Research (AACR)
June 22-24, 2020
Expanding the Therapeutic Potential of anti-PD-1 and anti-CTLA-4 Therapy with Innovative Fc Engineering and Rationale Combinations for the Treatment of Solid Tumors. Tanne, et al.
American Society of Clinical Oncology (ASCO)
May 29-31, 2020
AGEN1181, a Clinical Stage Fc-Engineered anti-CTLA-4 Antibody with Improved Therapeutic Potential for the Treatment of Patients with Advanced Malignancies. O'Day, et al.
Protein and Antibody Engineering Summit (PEGS)
November 18, 2019
New mechanistic insights from TME reconditioning by an Fc engineered anti-CTLA-4 antibody. Vincent, et al.
Cancer Cell
June 11, 2018
Selective FcgR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens. Waight, et al.
AGEN2373: CD137 Agonist Antibody
American Society of Clinical Oncology (ASCO)
June 3-7, 2021
Initial Findings of the First-in-human Phase I Study of AGEN2373, a Conditionally Active CD137 Agonist Antibody, in Patients (pts) With Advanced Solid Tumors. Tolcher, et al.
Society for Immunotherapy of Cancer (SITC)
November 9-14, 2020
AGEN2373 is a CD137 agonist antibody designed to leverage optimal CD137 and FcγR co-targeting to promote antitumor immunologic effects. Galand, et al.
Society for Immunotherapy of Cancer (SITC)
November 7-11, 2018
AGEN2373 is a Conditionally-Active Agonist Antibody Targeting the Co-Stimulatory Receptor CD137 for the Treatment of Human Malignancies. Galand, et al.
AGEN1327: Anti-TIGIT Antibody
Society for Immunotherapy of Cancer (SITC)
November 9-14, 2020
Anti-TIGIT antibodies require enhanced FcγR co-engagement for optimal T and NK cell-dependent anti-tumor immunity. Ward, et al.
American Association for Cancer Research (AACR)
March 29-April 3, 2019
FcgR Co-Engagement by Anti-TIGIT Monoclonal Antibodies Enhances T cell Functionality and Antitumor Immune Responses. Chand, et al.
Cancer Cell
June 11, 2018
Selective FcgR Co-Engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens. Waight, et al.
INCAGN02385: Anti-LAG-3 Antibody
American Association for Cancer Research (AACR)
April 14-18, 2018
INCAGN02385 is an Antagonist Antibody Targeting the Co-Inhibitory Receptor LAG-3 for the Treatment of Human Malignancies. Savitsky, et al.
INCAGN02390: Anti-TIM-3 Antibody
American Association for Cancer Research (AACR)
April 14-18, 2018
INCAGN02390, a Novel Antagonist Antibody That Targets the Co-Inhibitory Receptor TIM-3. Waight, et al.
INCAGN1876: GITR Agonist Antibody
American Association for Cancer Research (AACR)
April 1-5, 2017
INCAGN1876, a Unique GITR Agonist Antibody That Facilitates GITR Oligomerization. Gonzalez, et al.
American Association for Cancer Research (AACR)
April 16-20, 2016
A Novel Agonist Antibody (INCAGN01876) That Targets the Costimulatory Receptor GITR. Gonzalez, et al.
INCAGN1949: OX40 Agonist Antibody
American Association for Cancer Research (AACR)
April 1-5, 2017
INCAGN1949, an Anti-OX40 Antibody With an Optimal Agonistic Profile and the Ability to Selectively Deplete Intratumoral Regulatory T Cells. Gonzalez, et al.
American Association for Cancer Research (AACR)
April 16-20, 2016
INCAGN01949: A Novel Anti-OX40 Agonist Antibody With the Potential to Enhance Tumor Specific T-cell Responsiveness, While Selectively Depleting Intratumoral Regulatory T Cells. Gonzalez, et al.
VISION
Society for Immunotherapy of Cancer (SITC)
November 9-14, 2020
Beyond PD-L1: novel PD-1 biomarkers identified by driving T cell dysfunction in vitro. Pabla, et al.
AI Powered Drug Discovery and Manufacturing (AIDM)
February 27-28, 2020
Using Big Data and Machine Learning to Understand T cell Dysfunction in Human Tumors. Pabla, et al.
Society for Immunotherapy of Cancer (SITC)
November 6-10 2019
Driving T cell Dysfunction in Vitro for Rational Immunotherapy Design. Joyce, et al.
Cell therapy
Society for Immunotherapy of Cancer (SITC)
November 9-14 2020
AgenT-797, a novel allogenic and “off-the shelf” iNKT cell therapy promotes effective tumor killing. Burcu, et al.
Society for Immunotherapy of Cancer (SITC)
November 6-10 2019
TCR Fingerprinting and Off-Target Peptide Identification. Karapetyan, et al.
Frontiers in Immunology
October 22, 2019
TCR Fingerprinting and Off-Target Peptide Identification. Karapetyan, et al.
QS-21 Stimulon® Adjuvant
New England Journal of Medicine
September 15, 2016
Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. Cunningham, et al.
New England Journal of Medicine
November 17, 2011
First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children. RTS,S Clinical Trials Partnership, et al.
Expert Review of Vaccines
April 2011
Recent Clinical Experience With Vaccines Using MPL- And QS-21-Containing Adjuvant Systems. Garçon, et al.
Vaccine
August 11, 2011
Four Year Immunogenicity of the RTS,S/AS02(A) Malaria Vaccine in Mozambican Children During a Phase IIb Trial. Aide, et al.
The Journal of Infectious Diseases
July 1, 2011
Effect of the Pre-Erythrocytic Candidate Malaria Vaccine RTS,S/AS01E on Blood Stage Immunity in Young Children. Bejon, et al.
The Lancet Infectious Diseases
October 1, 2011
Safety and Efficacy of the RTS,S/AS01E Candidate Malaria Vaccine Given With Expanded-Programme-On-Immunisation Vaccines: 19 Month Follow-Up of a Randomised, Open-Label, Phase 2 Trial. Asante, et al.
Vaccine
November 3, 2011
Safety and Immunogenicity of Long HSV-2 Peptides Complexed with rhHsc70 in HSV-2 Seropositive Persons. Wald, et al.
Vaccine
November 3, 2011
A Heat Shock Protein Based Polyvalent Vaccine Targeting HSV-2: CD4(+) and CD8(+) Cellular Immunity and Protective Efficacy. Mo, et al.
Kidney International
February 1, 2010
Rapid, Enhanced, and Persistent Protection of Patients with Renal Insufficiency by AS02(V)-Adjuvanted Hepatitis B Vaccine. Surquin, et al.
New England Journal of Medicine
December 11, 2008
Safety and Immunogenicity of RTS,S/AS02D Malaria Vaccine in Infants. Abdulla, et al.
New England Journal of Medicine
December 11, 2008
Efficacy of RTS,S/AS01E Vaccine Against Malaria in Children 5 to 17 Months of Age. Bejon, et al.
Expert Opinion on Biological Therapy
June 12, 2008
Cancer Immunotherapy Targeting Tumour-Specific Antigens: Towards a New Therapy for Minimal Residual Disease. Brichard, et al.
Vaccine
March 4, 2008
Vaccine Adjuvant Systems Containing Monophosphoryl Lipid A and QS21 Induce Strong and Persistent Humoral and T Cell Responses Against Hepatitis B Surface Antigen in Healthy Adult Volunteers. Vandepapelière, et al.
The Journal of Immunology
July 15, 2005
Induction of Humoral and CD8+ T Cell Responses are Required for Protection Against Lethal Ebola Virus Infection. Warfiled, et. al.
Clinical Cancer Research
May 2002
T-cell Responses Against Tyrosinase 368-376(370D) Peptide in HLA*A0201+ Melanoma Patients: Randomized Trial Comparing Incomplete Freund's Adjuvant, Granulocyte Macrophage Colony-Stimulating Factor, and QS-21 as Immunological Adjuvants. Schaed, et al.
The Journal of Immunology
February 15, 2001
Oral QS-21 Requires Early IL-4 Help for Induction of Mucosal and Systemic Immunity. Boyaka, et al.
Vaccine
February 28, 2001
QS-21 Promotes an Adjuvant Effect Allowing for Reduced Antigen Dose During HIV-1 Envelope Subunit Immunization in Human. Evans, et al.
Vaccine
July 16, 2001
Three Double-Blind, Randomized Trials Evaluating the Safety and Tolerance of Different Formulations of the Saponin Adjuvant QS-21. Waite, et al.
The Journal of Infectious Diseases
November 1, 2009
Synthetic Malaria Peptide Vaccine Elicits High Levels of Antibodies in Vaccinees of Defined HLA Genotypes. Nardin, et al.
Vaccine
November 12, 1999
Comparison of the Effect of Different Immunological Adjuvants on the Antibody and T Cell Response to Immunization with MUC1-KLH and GD3-KLH Conjugate Cancer Vaccines. Kim, et al.
Journal of Virology
June 1998
Induction of Systemic and Mucosal Immune Responses to Human Immunodeficiency Virus Type 1 by a DNA Vaccine Formulated With QS-21 Saponin Adjuvant via Intramuscular and Intranasal Routes. Sasaki, et al.
New England Journal of Medicine
January 9, 1997
A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against Plasmodium Falciparum Malaria. RTS,S Malaria Vaccine Evaluation Group. Stoute, et al.
Carbohydrate Research
January 4, 1996
Structure of the saponin adjuvant QS-21 and its Base-Catalyzed Isomerization Product by 1H and Natural Abundance 13C NMR Spectroscopy. Jacobsen, et al.
Cancer Research
July 1, 1995
GM2-KLH Conjugate Vaccine: Increased Immunogenicity in Melanoma Patients After Administration With Immunological Adjuvant QS-21. Helling, et al.
The Journal of Immunology
April 15, 1992
Saponin Adjuvant Induction of Ovalbumin-Specific CD8+ Cytotoxic T Lymphocyte Responses. Newman, et al.
The Journal of Immunology
January 15, 1991
Separation and Characterization of Saponins With Adjuvant Activity From Quillaja Saponaria Molina Cortex. Kensil, et al.
AutoSynVaxTM: Individualized cancer neoantigen vaccine
Society for Immunotherapy of Cancer (SITC)
Novemeber 1, 2018
A Phase 1 Study of Safety and Tolerability of AGEN2003 Vaccine in Patients With Advanced Cancer. Wesolowski, et al.
American Association for Cancer Research (AACR)
April 1-5, 2017
Agenus' Next Generation Cancer Vaccine Platforms. Uduman, et al.
PhosphoSynVaxTM: Off-the-shelf cancer neoantigen vaccine
Nature
December 6, 2019
Murine Xenograft Bioreactors for Human Immunopeptidome Discovery. Heather, et al.
Touchoncology
October 17, 2019
Neoantigen Vaccine Delivery for Personalized Anticancer Immunotherapy – The PSV™ Platform. Myers
Society for Immunotherapy of Cancer (SITC)
November 7-11, 2018
Identification of Shared Phosphopeptide Tumor Targets in Colorectal Cancer for Novel Off-the-shelf Vaccine Development. Myers, et al.
Next Gen Immuno-Oncology Congress Presentation
June 21, 2018
The Remarkable Efficiency of Chaperone-based Synthetic Cancer Vaccines. Levey, PhD
American Association for Cancer Research (AACR)
April 1-5, 2017
Agenus' Next Generation Cancer Vaccine Platforms. Uduman, et al.
ProphageTM: Individualized Cancer Vaccine
Clinical Cancer Research
February 13, 2017
Autologous Heat Shock Protein Peptide Vaccination for Newly Diagnosed Glioblastoma: Impact of Peripheral PD-L1 Expression on Response to Therapy. Bloch, et al.
Neuro-Oncology
December 12, 2013
Heat-shock Protein Peptide complex-96 Vaccination for Recurrent Glioblastoma: A Phase II, Single-Arm Trial. Bloch, et al.
Clinical Cancer Research
August 7, 2012
Individual Patient-Specific Immunity Against High-Grade Glioma After Vaccination With Autologous Tumor Derived Peptides Bound to the 96 KD Chaperone Protein. Crane, et al.
Journal of Translational Medicine
January 29, 2010
Autologous Tumor-Derived Heat-shock Protein Peptide Complex-96 (HSPPC-96) in Patients with Metastatic Melanoma. Eton, et al.
Journal of Clinical Oncology
May 20, 2009
Survival Update from a Multicenter, Randomized, Phase III Trial of Vitespen Versus Observation as Adjuvant Therapy for Renal Cell Carcinoma in Patients at High Risk of Recurrence [meeting abstract]. Wood, et al.
Expert Opinion on Biological Therapy
February 2009
Treating Human Cancers With Heat Shock Protein-Peptide Complexes: The Road Ahead. Srivastava, et al.
The Lancet
July 3, 2008
An Adjuvant Autologous Therapeutic Vaccine (HSPPC-96; Vitespen) Versus Observation Alone for Patients at High Risk of Recurrence After Nephrectomy for Renal Cell Carcinoma: A Multicentre, Open-Label, Randomised Phase III Trial. Wood, et al.
Journal of Clinical Oncology
May 20, 2008
Phase II Feasibility Study of Autologous Vaccine (HSPPC-96) in Patients with Resectable Lung Cancer [meeting abstract]. Santis, et al.
British Journal of Cancer
April 22, 2008
Vaccination of Metastatic Renal Cell Carcinoma Patients with Autologous Tumour-Derived Vitespen Vaccine: Clinical Findings. Jonasch, et al.
Journal of Clinical Oncology
February 20, 2008
Phase III Comparison of Vitespen, an Autologous Tumor-Derived Heat Shock Protein gp96 Peptide Complex Vaccine, with Physician's Choice of Treatment for Stage IV Melanoma: the C-100-21 Study Group. Testori, et al.
Digestive Diseases and Sciences
April 10, 2007
A Phase I Pilot Study of Autologous Heat Shock Protein Vaccine HSPPC-96 in Patients With Resected Pancreatic Adenocarcinoma . Maki, et al.
Cancer
January 1, 2007
Experience With Heat Shock Protein-Peptide Complex 96 Vaccine Therapy in Patients With Indolent Non-Hodgkin Lymphoma . Oki, et al.
Clinical Cancer Research
June 15, 2005
Combination of Imatinib Mesylate With Autologous Leukocyte-Derived Heat Shock Protein and Chronic Myelogenous Leukemia. Li, et al.
Cancer Research
May 1 2005
Natural Killer and NK-Like T Cell Activation in Colorectal Carcinoma Patients Treated With Autologous Tumor-Derived Heat Shock Protein 96 . Pilla, et al.
The Journal of Immunology
October 1, 2003
Human Tumor-Derived Heat Shock Protein 96 Mediates in Vitro Activation and in Vivo Expansion of Melanoma And Colon Carcinoma-Specific T Cells . Rivoltini, et al.
Clinical Cancer Research
August 15, 2003
Vaccination With Autologous Tumor-Derived Heat-Shock Protein gp96 After Liver Resection for Metastatic Colorectal Cancer . Mazzaferro, et al.
Journal of Clinical Oncology
October 15, 2002
Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings. Belli, et al.
Cancer Research
January 1, 2001
Human Heat Shock Protein 70 Peptide Complexes Specifically Activate Antimelanoma T Cells. Castelli, et al.
International Journal of Cancer
September 13, 2000
Immunization of Cancer Patients With Autologous Cancer-Derived Heat Shock Protein gp96 Preparations: A Pilot Study. Janetzki, et al.
Other Publications
Frontiers in Immunology
August 7, 2019
Mutation-Derived Neoantigens for Cancer Immunotherapy. Castle, et al.